Overview Financials News + Filings Key Docs Charts Ownership Insiders
All All (ex-4s) 10-K 10-Q 8-K 3,4,5 Proxy Prospectus Other
Tags Quarterly results
|
Aerovate Therapeutics, Inc. (AVTE)
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
08/14/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
08/14/2023 |
8-K
| Quarterly results |
08/09/2023 |
4
| Dake Benjamin T (SEE REMARKS) has filed a Form 4 on Aerovate Therapeutics, Inc.
Txns:
| Sold 9,742 shares
@ $15.4785, valued at
$150.8k
Sold 541 shares
@ $16.2451, valued at
$8.8k
Exercised 905 options to buy
@ $1.74, valued at
$1.6k
Exercised 1,507 options to buy
@ $1.74, valued at
$2.6k
Exercised 1,018 options to buy
@ $2.14, valued at
$2.2k
Exercised 6,853 options to buy
@ $2.14, valued at
$14.7k
|
|
08/07/2023 |
144
| Form 144 - Report of proposed sale of securities: |
08/01/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
07/28/2023 |
144
| Form 144 - Report of proposed sale of securities: |
07/19/2023 |
4
| NOYES TIMOTHY P (CEO) has filed a Form 4 on Aerovate Therapeutics, Inc.
Txns:
| Sold 4,522 shares
@ $18.1106, valued at
$81.9k
Exercised 4,522 options to buy
@ $2.14, valued at
$9.7k
|
|
07/17/2023 |
144
| Form 144 - Report of proposed sale of securities: |
07/11/2023 |
4
| Dable Habib J (Director) has filed a Form 4 on Aerovate Therapeutics, Inc.
Txns:
| Granted 25,000 options to buy
@ $18.08, valued at
$452k
|
|
07/11/2023 |
3
| Dable Habib J (Director) has filed a Form 3 on Aerovate Therapeutics, Inc. |
07/11/2023 |
8-K
| Quarterly results |
07/07/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
07/07/2023 |
4
| NIVEN RALPH (CHIEF SCIENTIFIC OFFICER) has filed a Form 4 on Aerovate Therapeutics, Inc.
Txns:
| Sold 2,031 shares
@ $17.2337, valued at
$35k
Sold 219 shares
@ $17.8686, valued at
$3.9k
Exercised 450 options to buy
@ $1.74, valued at
$783 Exercised 200 options to buy
@ $1.74, valued at
$348 Exercised 200 options to buy
@ $2.14, valued at
$428 Exercised 650 options to buy
@ $2.14, valued at
$1.4k
Exercised 750 options to buy
@ $2.14, valued at
$1.6k
|
|
07/06/2023 |
144
| Form 144 - Report of proposed sale of securities: |
07/05/2023 |
144
| Form 144 - Report of proposed sale of securities: |
07/05/2023 |
4
| NOYES TIMOTHY P (CEO) has filed a Form 4 on Aerovate Therapeutics, Inc.
Txns:
| Sold 10,000 shares
@ $18, valued at
$180k
Exercised 10,000 options to buy
@ $2.14, valued at
$21.4k
|
|
07/03/2023 |
144
| Form 144 - Report of proposed sale of securities: |
06/08/2023 |
4
| RA CAPITAL MANAGEMENT, L.P. (10% Owner) has filed a Form 4 on Aerovate Therapeutics, Inc.
Txns:
| Granted 12,500 options to buy
@ $16.3, valued at
$203.8k
|
|
06/08/2023 |
4
| Dake Benjamin T (SEE REMARKS) has filed a Form 4 on Aerovate Therapeutics, Inc.
Txns:
| Sold 10,268 shares
@ $16.2798, valued at
$167.2k
Sold 15 shares
@ $16.975, valued at
$254.6 Exercised 905 options to buy
@ $1.74, valued at
$1.6k
Exercised 1,507 options to buy
@ $1.74, valued at
$2.6k
Exercised 1,018 options to buy
@ $2.14, valued at
$2.2k
Exercised 6,853 options to buy
@ $2.14, valued at
$14.7k
|
|
06/08/2023 |
4
| Santel Donald J (Director) has filed a Form 4 on Aerovate Therapeutics, Inc.
Txns:
| Granted 12,500 options to buy
@ $16.3, valued at
$203.8k
|
|
06/08/2023 |
4
| Katabi Maha (10% Owner) has filed a Form 4 on Aerovate Therapeutics, Inc.
Txns:
| Granted 12,500 options to buy
@ $16.3, valued at
$203.8k
|
|
06/08/2023 |
4
| GRAYZEL DAVID S. (Director) has filed a Form 4 on Aerovate Therapeutics, Inc.
Txns:
| Granted 12,500 options to buy
@ $16.3, valued at
$203.8k
|
|
06/08/2023 |
4
| Resnick Joshua (Director) has filed a Form 4 on Aerovate Therapeutics, Inc.
Txns:
| Granted 12,500 options to buy
@ $16.3, valued at
$203.8k
|
|
06/08/2023 |
4
| Iwicki Mark T (Director) has filed a Form 4 on Aerovate Therapeutics, Inc.
Txns:
| Granted 12,500 options to buy
@ $16.3, valued at
$203.8k
|
|
06/08/2023 |
4
| Dorval Allison (Director) has filed a Form 4 on Aerovate Therapeutics, Inc.
Txns:
| Granted 12,500 options to buy
@ $16.3, valued at
$203.8k
|
|
06/08/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
06/07/2023 |
4
| NIVEN RALPH (CHIEF SCIENTIFIC OFFICER) has filed a Form 4 on Aerovate Therapeutics, Inc.
Txns:
| Sold 2,250 shares
@ $16.256, valued at
$36.6k
Exercised 450 options to buy
@ $1.74, valued at
$783 Exercised 200 options to buy
@ $1.74, valued at
$348 Exercised 200 options to buy
@ $2.14, valued at
$428 Exercised 650 options to buy
@ $2.14, valued at
$1.4k
Exercised 750 options to buy
@ $2.14, valued at
$1.6k
|
|
06/06/2023 |
144
| Form 144 - Report of proposed sale of securities: |
06/05/2023 |
144
| Form 144 - Report of proposed sale of securities: |
05/23/2023 |
4
| Gillies Hunter (CHIEF MEDICAL OFFICER) has filed a Form 4 on Aerovate Therapeutics, Inc.
Txns:
| Sold 65 shares
@ $19.5, valued at
$1.3k
Exercised 65 options to buy
@ $1.74, valued at
$113.1 |
|
05/19/2023 |
4
| Gillies Hunter (CHIEF MEDICAL OFFICER) has filed a Form 4 on Aerovate Therapeutics, Inc.
Txns:
| Sold 1,090 shares
@ $19.5925, valued at
$21.4k
Exercised 1,090 options to buy
@ $1.74, valued at
$1.9k
|
|
05/19/2023 |
144
| Form 144 - Report of proposed sale of securities: |
05/17/2023 |
144
| Form 144 - Report of proposed sale of securities: |
05/09/2023 |
4
| NIVEN RALPH (CHIEF SCIENTIFIC OFFICER) has filed a Form 4 on Aerovate Therapeutics, Inc.
Txns:
| Sold 2,045 shares
@ $20.793, valued at
$42.5k
Sold 205 shares
@ $21.6348, valued at
$4.4k
Exercised 450 options to buy
@ $1.74, valued at
$783 Exercised 200 options to buy
@ $1.74, valued at
$348 Exercised 200 options to buy
@ $2.14, valued at
$428 Exercised 650 options to buy
@ $2.14, valued at
$1.4k
Exercised 750 options to buy
@ $2.14, valued at
$1.6k
|
|
|
|
|